A multicenter observational study on the efficacy and safety of systemic therapy for hepatocellular carcinoma

A multicenter observational study on the efficacy and safety of systemic therapy for hepatocellular carcinoma - A multicenter observational study on the efficacy and safety of systemic therapy for hepatocellular carcinoma

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053532

Enrollment

1100

Registered

2024-02-03

Start date

2023-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients administered with either sorafenib, lenvatinib, atezolizumab plus bevacizumab, duruvalumab with/without tremelimumab, regorafenib, ramucirumab or cabozantinib for hepatocellular carcinoma at the participating institutions between May 2009 and December 2023

Exclusion criteria

Exclusion criteria: Patient without adequate baseline information due to reasons such as an initiation of treatment at another institution Patients without adequate follow-up period for reasons such as transferring to another hospital before radiological assessment of treatment response Patients considered inappropriate as subjects for this study by the principal investigator or researchers involved in the study

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
Overall survival Best overall response Objective response rate Disease control rate Proportion of patients undergoing curative conversion therapy Treatment-related adverse events	—

Countries

Japan

Contacts

Public ContactMasayuki Ueno

Graduate School of Medicine, Kyoto University Department of Gastroenterology and Hepatology

masayukiu@kuhp.kyoto-u.ac.jp075-751-3111

Outcome results